Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Research & Development (2024 - 2025)

Caris Life Sciences has reported Research & Development over the past 2 years, most recently at $31.8 million for Q4 2025.

  • Quarterly results put Research & Development at $31.8 million for Q4 2025, up 17.47% from a year ago — trailing twelve months through Dec 2025 was $105.6 million (changed N/A YoY), and the annual figure for FY2025 was $101.6 million, down 10.83%.
  • Research & Development for Q4 2025 was $31.8 million at Caris Life Sciences, up from $21.6 million in the prior quarter.
  • Over the last five years, Research & Development for CAI hit a ceiling of $31.8 million in Q4 2025 and a floor of $21.6 million in Q3 2025.